444.00
-11.02(-2.42%)
Currency In USD
Address
675 West Kendall Street
Cambridge, MA 02142
United States of America
Phone
617 551 8200
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
2230
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | Chief Executive Officer & Director | 4.25M | 1963 |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board & Independent Director | 105,000 | 1945 |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development | 1.23M | 1968 |
| Mr. Tolga Tanguler M.B.A. | Executive Vice President & Chief Commercial Officer | 1.31M | 1973 |
| Dr. Pushkal P. Garg M.D. | Chief Medical Officer and Executive Vice President of Development & Medical Affairs | 1.42M | 1968 |
| Mr. Jeffrey V. Poulton M.B.A. | Chief Financial Officer & Executive Vice President | 1.43M | 1968 |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer | 0 | N/A |
| Ms. Christine Regan Lindenboom | Chief Corporate Communications Officer | 0 | 1982 |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer | 0 | N/A |
| Mr. Robert W. Hesslein Esq., J.D. | Executive Vice President, Chief Legal Officer & Corporate Secretary | 0 | 1953 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.